Myriad Genetics closed a $200 million credit deal with OrbiMed to support its growth and operational objectives. The credit includes $125 million funded with an option for an additional $75 million until mid-2027 and replaces a prior $115 million facility. With favorable interest rates tied to SOFR plus margin, Myriad aims to bolster capital flexibility ahead of upcoming financial disclosures and strategic initiatives.